Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

p>Increase (decrease) in cash from:

Inventory (42) (27)

Accounts receivable (1,392) 706

Grants receivable 112 16

Research tax credit receivable 1,603 1,449

Accounts payable

and accrued expenses (98) 463

Accrued compensation 235 (16)

Other current liabilities - -

Prepaid expenses and other assets (403) (61)

Deferred income, short term 1,076 (240)

Deferred income, long term (860) (372)

Net cash used in operating activities (3,940) (4,934)

INVESTING ACTIVITIES

Purchase of property and equipment (757) (1,051)

Payment of patent and acquisition

of other intangibles 416 174

Net cash used in investing activities (340) (877)

FINANCING ACTIVITIES

Proceeds from loans 13,522 -

Repayment of loans and capital lease (414) 345

Issuance of shares (net of fees) 1,585 12,977

Net cash provided by (used in)

financing activities 14,693 13,322

Net increase (decrease) in cash

and cash equivalents 10,413 7,511

Effects of exchange rate on cash (41) (141)

Cash and cash equivalents, beginning of period 13,601 23,972

Cash and cash equivalents, end of period 23,972 31,342 <
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Biscayne Pharmaceuticals, Inc ., today announced ... hormone-releasing hormone (GHRH) technology will be discussed in a ... The data show that the family of receptors for ... present on many primary breast cancer cells regardless of ... could have broad anti-cancer potential in breast cancer. 1 ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo ... EMR/EHR Clinical Data Integration with EDC Systems ” at ... DC on June 14th-18th. , During the presentation, Glenn ... with EDC, and will examine the value of patient ... electronic health records/electronic medical records integration. , The ...
(Date:5/28/2015)... Rochelle, Virginia (PRWEB) May 28, 2015 ... Partners LLC announced today that Roger L. Williams, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:5/27/2015)... Mass. , May 27, 2015 ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today announced that it has commenced a public ... to purchase shares of its common stock and ... common stock. The shares of common stock, warrants ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3
... to Vice President and Chief Financial ... Transition to Consultant Role, SOUTH SAN FRANCISCO, ... ) today reported 2007 fourth quarter and year-end,financial ... 2008,based on commercialization plans for FDA-approved Zingo(TM) (lidocaine,hydrochloride ...
... Mass., Feb. 11 Millstone Medical,Outsourcing announced ... minimal,interruption after last week,s tornado by relocating ... Center address is 4740 Shelby,Drive, Memphis, TN, ... the,initial location, the new Millstone facility provides ...
... Data Presented at the 66th Annual Meeting of the American Academy ... ... clinical research from AGI,Dermatics indicates that L-Ergothioneine (EGT) and its natural receptor,OCTN- ... more,effective than idebenone in reducing harmful free radicals in photoaged,skin. The data ...
Cached Biology Technology:Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 2Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 3Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 4Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 5Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 6Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 7Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 8Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook 9Millstone Medical Outsourcing Relocates Memphis Distribution Center Within 72 Hours of Tornado Disaster 2AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skin's Natural Antioxidant System 2
(Date:5/14/2015)... May 14, 2015 Research and Markets ... "Fingerprint Sensors Market in Smart Mobile Devices " ... believes that 2014 was a watershed year for fingerprint ... of ,Apple Pay,. Apple gave fingerprint sensors a raison ... service. Fingerprint sensors are a must-have feature in flagship ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Diabetes Center have found genetic regions that, when defective, allow ... a series of mis-steps that lead to type 1 diabetes. ... Immunity, the researchers are now trying to hone in on ... , “The significance of this study is that we found ...
... found to defy the most basic tenet of sexual ... sex, according to Howard Hughes Medical Institute researchers at ... 2005, issue of Nature, the researchers reported that, in ... "sex" can mate and produce offspring. Infection with the ...
... identified the proteins that allow specific brain cells to "change ... the cell. The findings, described in the March 24 issue ... day using it to protect cells that die in Lou ... what comes into the living room, these brain cells are ...
Cached Biology News:Genetic defects give the immune system the green light to attack the pancreas 2Genetic defects give the immune system the green light to attack the pancreas 3Same-Sex Mating Discovered in a Toxic Fungus 2Same-Sex Mating Discovered in a Toxic Fungus 3Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3
Request Info...
... is a nonspecific endonuclease that degrades double-and ... hydrolyzing phosphodiester linkages, producing mono and oligonucleotides ... Ambion's RNase-free DNase I is of the ... degrade DNA in the presence of RNA ...
hnRNP U (H-94)...
... GELase™ Agarose Gel-Digesting Preparation contains a unique ... simple, quantitative recovery of intact DNA and ... gels following electrophoresis in TAE, TBE, MOPS, ... digested directly in the TAE, TBE, MOPS, ...
Biology Products: